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Abstract
Spontaneously arising (‘de novo’) mutations play an important role in medical genetics. For 
diseases with extensive locus heterogeneity – such as autism spectrum disorders (ASDs) – the 
signal from de novo mutations (DNMs) is distributed across many genes, making it difficult to 
distinguish disease-relevant mutations from background variation. We provide a statistical 
framework for the analysis of DNM excesses per gene and gene set by calibrating a model of de 
novo mutation. We applied this framework to DNMs collected from 1,078 ASD trios and – while 
affirming a significant role for loss-of-function (LoF) mutations – found no excess of de novo LoF 
mutations in cases with IQ above 100, suggesting that the role of DNMs in ASD may reside in 
fundamental neurodevelopmental processes. We also used our model to identify ~1,000 genes that 
are significantly lacking functional coding variation in non-ASD samples and are enriched for de 
novo LoF mutations identified in ASD cases.
Exome sequencing has allowed for the identification of de novo (newly arising) events and 
has already been effectively put to use in identifying causal variants in rare, Mendelian 
diseases. In the case of Kabuki syndrome, the observation of a de novo mutation (DNM) in 
MLL2 in 9 out of the10 patients strongly implicated the loss of MLL2 function as causal1. 
The conclusion that MLL2 is important in Kabuki syndrome etiology based on the de novo 
findings relies upon the unlikely accumulation of independent and infrequently occurring 
events in the vast majority of these unrelated cases. By contrast, DNMs play a smaller role 
in the pathogenesis of heritable complex traits, such as autism spectrum disorders (ASDs), 
and associated DNMs are spread across multiple genes. These differences in the etiologic 
architecture of complex traits make the task of identifying “causal” genes considerably more 
challenging. For example, recent exome sequencing studies demonstrated a significant 
excess of de novo loss-of-function (LoF) mutations in ASD cases, but lacked the ability to 
directly implicate more than a very few genes2–6.
The main complicating factor for interpreting the number of observed DNMs for a particular 
gene is the background rate of de novo mutation, which can vary greatly between genes. As 
more individuals are sequenced, multiple DNMs will inevitably be observed in the same 
gene by chance. However, if de novo mutation plays a role in a given disease, then we 
would expect to find that genes associated to disease should contain more DNMs than 
expected by chance.
Here, we develop a statistical model of de novo mutation in order to evaluate the findings 
from exome sequencing data. With this model, we establish a statistical framework to 
evaluate the rate of DNMs not only on a per-gene basis (in a frequentist manner analogous 
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to common genome-wide association analysis), but also globally and by gene set. We further 
use this model to predict the expected amount of rare standing variation per gene and to 
detect those genes that are significantly and specifically deficient in functional variation – 
likely reflecting processes of selective constraint. Consequently, since selection has reduced 
standing functional variation in these genes, it is reasonable to hypothesize that mutations in 
these genes are more likely to be deleterious.
We used the mutational model along with our list of highly constrained genes to evaluate the 
relationship between de novo mutation and ASDs. Most of the families employed in these 
analyses were included in a set of previous studies of de novo mutation, which reported an 
overall excess of de novo LoF mutations in ASD cases, as well as multiple DNMs in specific 
genes2–5. We build on those studies to examine the aggregate rates of DNMs, the excess of 
multiply mutated genes, and the overlap of DNMs with gene sets, which highlights the 
complex relationship between intellectual functioning and the genetic architecture of ASD.
Results
Basis of the mutational model
Accurate estimation of the expected rate of de novo mutation in a gene requires a precise 
estimate of each gene’s mutability. While gene length is an obvious factor in a gene’s 
mutability, local sequence context is also a well-known source of mutation rate differences7. 
Accordingly, we extended a previous model of de novo mutation based on sequence context 
and developed gene-specific probabilities for different types of mutation: synonymous, 
missense, nonsense, essential splice site, and frameshift (Online Methods and 
Supplementary Fig. 1)3. All probabilities of mutation can be found in Supplementary Table 
1. Underscoring the importance of the sequence context factors in the model, this genome-
wide rate yields an expected mutation rate of 1.67×10−8 for the exome alone. Using counts 
of rare (minor allele frequency < 0.001) synonymous variants identified in the NHLBI’s 
Exome Sequencing Project (ESP), we found that our per-gene probabilities of mutation were 
significantly more correlated (r=0.940) with these counts than gene length alone (p < 10−16; 
Online Methods).
Having established accurate per-gene probabilities of mutation, we could then investigate 
the rates and distribution of DNMs found in sequencing studies. Specifically, we wished to 
systematically assess a) whether cases had genome-wide excesses of certain functional 
categories of de novo mutation; b) whether individual genes could be associated via de novo 
mutation with genome-wide statistical significance; c) whether specific sets of genes 
collectively showed significant enrichment of de novo mutations and d) whether there were 
genome-wide excesses of genes with multiple de novo mutations. Below we demonstrate the 
utility of the statistical framework to address all of these questions with respect to recently 
generated autism and intellectual disability family exome sequencing data.
Identifying genes under selective constraint
There has been a long standing interest in identifying genes in the human genome that are 
sensitive to mutational changes, as these genes would be the most likely to contribute to 
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disease. Recent work made use of the ESP data to create a metric evaluating the proportion 
of common functional variation in each gene, thereby identifying genes that appeared to be 
intolerant of mutation8. Along these lines, we correlated our calculated per-gene 
probabilities of mutation with the observed counts of rare missense variants in the ESP data 
set. In contrast to the high consistency between predicted synonymous mutation rates and 
observed synonymous counts (expected if the category is under no specific selection), we 
observed a significant number of genes with severe deficit of missense variants compared to 
the expectation generated from predicted mutation rates. Such a deficit is consistent with 
strong evolutionary constraint: when damaging mutations arise, they are quickly removed 
from the population by purifying selection. To avoid erroneously identified constrained 
genes, we removed 134 genes with either significantly elevated or depressed synonymous 
and nonsynonymous rates (both p < 0.001; Online Methods).
Comparing both the synonymous and missense predictions of our model to the ESP data set, 
we identified a list of excessively constrained genes (p < 0.001) that represent roughly 5% of 
all genes (Supplementary Table 2). A high proportion of the most significantly constrained 
genes (missense constraint p < 1×10−6) had autosomal or X-linked dominant, largely 
sporadic, Mendelian disease entries listed in OMIM (n=27/86). By contrast, a set of genes 
for which the missense constraint was very close to expectation (n=111, −0.01 < Z < 0.01) 
had only two de novo or dominant disease inheritance entries in OMIM, which was 
significantly different from the highly constrained set (p < 10−8). For the 86 most highly 
constrained genes, no autosomal recessive Mendelian disorders have been documented. 
However, 11 of the 111 average constrained genes have been identified as causes of 
autosomal recessive Mendelian disorders (p < 0.003), underscoring the lack of strong 
constraint induced by recessive inheritance models.
Mutation rates for ASD and ID
We applied the model to two primary data sets: published results from ASD sequencing 
studies2–6 with a collection of additional unpublished ASD trios, and published results from 
patients with severe intellectual disability9,10. Table 1a shows the comparison between the 
predicted number of mutations per exome and the observed data from the 1,078 ASD cases 
as well as 343 sequenced unaffected siblings2–6. The model’s predictions match the 
observed data for the unaffected siblings well, but the cases show a significant excess of de 
novo LoF mutations consistent with the findings of the individual sequencing studies 
(p=2.05×10−7). Using our model to simulate null DNM sets, we found that there are 
significantly more genes with two or more de novo LoF mutations than would be expected 
by chance (p < 0.001, 6 observed when less than one was expected; Supplementary Table 3). 
Importantly, while we do not observe a global excess of de novo missense mutations, we do 
observe an excess of genes with two or more functional (LoF or missense) de novo 
mutations (observed 48 such genes when the average expected is 27; p < 0.001) and genes 
with two or more de novo missense mutations alone (observed 33 such genes when average 
expectation was 21, p=0.007 for missense, Table 1b). No such excess of genes containing 
multiple DNMs was seen in the unaffected siblings (Table 1b). Of note, our framework also 
supports the assessment of many other weightings and combinations of alleles – such as 
missense variants only (optimal for pure gain-of-function disease models), predicted 
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damaging missense variants only, and exact probability estimates for specific combinations 
of LoF and missense variants - than those shown above.
Table 2 lists some of the genes that have two or more LoF de novo mutations across the 
1,078 ASD subjects. The results for all genes can be found in Supplementary Table 4. A 
conservative significance threshold of 1×10−6 was used, correcting for 18,271 genes and two 
tests. Considering this set of 1,078 trios as a single experiment, two genes – DYRK1A and 
SCN2A – exceeded this conservative genome-wide significance for more de novo LoF 
mutations than predicted. SCN2A also had significantly more functional de novo mutations 
than expected. CHD8, with three de novo LoF mutations and one missense, was very close 
to the significance threshold in these studies (p=1.76×10−6 for LoF; p=3.20×10−5 for 
functional). However, a recent targeted sequencing study found 7 additional CHD8 de novo 
LoF mutations in ASD cases11. This brought the total number of de novo LoF mutations in 
CHD8 to 10, which was highly significant (p=8.38×10−20 when accounting for the total 
number of trios – 2,750 – examined in the combination of the targeted and exome-wide 
study). These results offer the encouraging point that, as with GWAS, larger collaborative 
trio exome efforts will define unambiguous risk factors. It is important to note, however, that 
not all genes with a large number of de novo mutations in them had significant p-values. For 
example, TTN had four missense DNMs in ASD cases, but a p-value that is not even 
nominally significant due to the enormous size of the gene (p=0.18). Even having two de 
novo LoF mutations was on occasion not enough to provide compelling significance (POGZ, 
two frameshifts, p=8.93×10−5). In comparison, none of the genes found to contain multiple 
DNMs in the unaffected siblings crossed the significance threshold (Supplementary Table 
5).
These analyses were also applied to the results from the sequencing studies of moderate to 
severe (IQ < 60) intellectual disability9,10. Intellectual disability, like ASD, showed a 
significant excess of LoF DNMs (p=6.49×10−7; Table 3a). Even with a much smaller 
sample size (n=151), there were genes with significantly more LoF and functional DNMs 
than predicted by the model (Table 4). The intellectual disability data also have significantly 
more genes with multiple de novo missense, LoF, and functional mutations than predicted 
(p=0.009 for missense, p < 0.001 for LoF and functional).
In our ASD sample, we then investigated the rate of de novo events as a function of IQ; 
roughly 80% of this sample had an IQ assessment attempted. We found that the rate of de 
novo LoF mutation in ASD cases with a measured IQ above average was no different than 
expectation (IQ ≥ 100; n=229; 0.08 de novo LoF mutations per exome compared to expected 
0.09, p=0.59). By contrast, the rate in the rest of the sample was substantially higher than 
expectation (n=572; rate of 0.17 de novo LoF mutations per exome, p=1.17×10−10). 
Furthermore, when directly compared (rather than to our expectation), these two groups 
were significantly different from each other, confirming a difference in genetic architecture 
among ASDs as a function of IQ (Supplementary Table 6, p < 0.001). These conclusions are 
unchanged in separate analyses of nonverbal and verbal IQ as well as full scale IQ 
(Supplementary Table 6).
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Gene set enrichment
Given the significant global excess of de novo LoF mutations in ASD cases, we wanted to 
evaluate whether the set of genes harboring de novo LoF mutations had significant overlap 
with several sets of genes proposed as relevant to autism or describing biochemical 
pathways. We used the probabilities of mutation to determine the fraction of LoF mutations 
expected to fall into the given gene set. We then used the binomial distribution to evaluate 
the number of observed LoF mutations overlapping the set compared to the established 
expectation. When we applied this analysis to a set of 112 genes reported as disrupted in 
individuals with ASD or autistic features, we observed no enrichment of de novo LoF 
mutations (Fig. 1, “Betancur”)12. By contrast, we applied this analysis to a recent study of 
842 genes found to interact with the Fragile X mental retardation protein (FMRP) in vivo 
and found a highly significant overlap (2.3-fold enrichment, p < 0.0001, Fig. 1)2,13. This 
enrichment with the targets of FMRP holds even when removing the DNMs identified in the 
Iossifov et al study that initially reported an enrichment of DNMs in ASD cases with 
FMRP-associated genes (2.5-fold enrichment, p < 0.0001)2.
We then evaluated the group of individuals from the ASD studies who had a de novo LoF 
event in one of the targets of FMRP. On average, these cases were enriched for having a 
measured IQ < 100 (Fisher’s exact p=4.01×10−4; Supplementary Table 7) as well as 
significantly reduced male:female ratio (p=0.02; Supplementary Table 8) as compared to the 
remaining sequenced cases (Supplementary Note). These individuals represent about 3% of 
the total sample, when at most a 1% overlap would be expected. The estimated odds ratio 
(OR) of de novo LoF events in the set of FMRP target genes was around 6, very similar to 
the OR estimated for large CNVs that disrupt multiple genes14. In addition, the OR for the 
published cases of moderate to severe intellectual disability noted above (IQ < 60; not 
ascertained for ASDs) having a de novo LoF event in the set of FMRP targets was roughly 
10.
The same analysis was applied to the list of de novo LoF events from unaffected siblings of 
ASD cases and additional control individuals (n=647)2,4,5,15. There was a significant 
enrichment when evaluating the overlap with the set of autism related genes (p=0.0095, Fig. 
1). However, no significance was observed for the overlap with the in vivo targets of FMRP. 
The list of de novo LoF mutations from the intellectual disability individuals, on the other 
hand, was significant for both sets (Supplementary Fig. 2). Even the de novo missense 
mutations found in the intellectual disability cases showed significant overlap with both sets 
under study (p=0.02 for autism-related genes, p < 0.0001 for the targets of FMRP, 
Supplementary Fig. 2).
Evaluating constrained genes
We further applied the enrichment analysis to our set of constrained genes and found that 
they contained more de novo LoF mutations than expected by chance (2.3-fold enrichment, 
p < 0.0001, Fig. 1). A greater fold enrichment was observed when focusing on the subset of 
constrained genes that were also identified in the FMRP study (3.0-fold enrichment, p < 
0.0001, Fig. 1)13. We note that the FMRP targets have a significant overlap with the 
constrained set of genes (odds ratio = 1.29, p < 0.0001), which is consistent with the report 
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that the targets of FMRP are under greater purifying selection than expected2. All 
enrichments were demonstrated to be independent of gene size (Supplementary Note).
The genes that contained a de novo missense or LoF mutation in the cases of intellectual 
disability also showed a significant enrichment for both the constrained gene set and the set 
of constrained targets of FMRP (p < 0.0001 for all lists). In comparison, no enrichment was 
found with either set and the list of genes that had a de novo LoF mutation in unaffected 
siblings and control individuals.
In addition to treating constraint as a dichotomous trait, we also evaluated the missense Z 
score for each of the genes with a de novo LoF mutation. We found that the distribution of 
missense Z scores for genes with a de novo LoF mutation in unaffected individuals was no 
different from the overall distribution of scores (Fig. 2; Wilcoxon p=0.8325). By contrast, 
both the genes with a de novo LoF mutation in ASD and intellectual disability cases had 
values significantly shifted towards high constraint (Wilcoxon p < 10−6 for both). 
Furthermore, we compared the distribution of Z scores between each of the three groups. 
Both the ASD and intellectual disability distributions were significantly different from the 
distribution of missense Z scores for unaffected individuals (p=0.0148 and 0.0012, 
respectively). The intellectual disability missense Z scores were also significantly higher 
than the ASD values (p=0.0319).
When evaluating the ASD cases split by IQ group, we found no enrichment of de novo LoF-
containing genes with either constrained genes and targets of FMRP in the group with IQ ≥ 
100 (p > 0.5 for both sets of genes) but very strong enrichment in the set with IQ < 100 (p < 
0.0001 for both sets of genes). These results reinforce the variable contribution of de novo 
LoF mutations across subsets of ASD cases.
Comparison of constrained genes with existing methods
Identifying constrained genes by comparing observed nonsynonymous sites to expectation is 
conceptually similar to the traditional approach of detecting selective pressure by comparing 
observed nonsynonymous sites to observed synonymous sites (e.g. dN/dS) that has been used 
extensively. Our approach should in principle achieve greater statistical power to detect 
constrained genes; comparison of an observation to expectation is statistically more 
powerful than contrasting that observation with a generally smaller second observation – the 
number of observed synonymous variants. In order to investigate this claim, we identified 
genes that had significant evidence for selective constraint using the dN/dS metric (i.e. their 
ratio of synonymous and nonsynonymous sites deviated the genome-wide average at p < 
0.001, Supplementary Note). There were only 377 of these genes, over half of which 
overlapped with the constrained gene list defined by our method (n=1003, overlap 237 
genes). The genes identified as significantly constrained by only our metric – the top 10 of 
which include RYR2, MLL, MLL2, and SYNGAP1 – are still significantly enriched for 
known causes of autosomal and X-linked dominant forms of Mendelian disease (p=5 × 
10−4). We therefore conclude that the model-based approach to identifying constrained 
genes adds substantial power to traditional approaches – the importance of this increased 
power to detect constraint in further articulated in the ASD and ID analyses below.
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Several groups have previously published approaches, and specific gene sets from them, that 
are also aimed at identifying genes under excessive purifying selection or generally 
intolerant of functional mutation. Bustamante et al16 expanded on the McDonald-Kreitman 
framework17 contrasting fixed differences in the primate lineage to polymorphic differences 
in humans to identify a set of genes under weak negative selection, while more recently 
Petrovski et al8 utilized the excess of rare versus common missense variation within humans 
to flag genes intolerant of functional variation. We found a reasonable correlation between 
our metric of constraint and Petrovski’s Residual Variation Intolerance Score (RVIS; 
Supplementary Fig. 3)8. A comparison of these approaches as applied to prioritization of 
known haploinsufficient genes as well as the autism de novo LoF mutations described here 
are provided in the Supplementary Note, demonstrating the two human-only approaches 
(constraint and RVIS) performing better on these tasks of identifying severely impactful 
medical genetics lesions in modern humans (Supplementary Table 9). Intriguingly, both of 
these other approaches utilize independent information from each other and from our 
approach (which uses the absence of rare functional variation versus expectation within 
humans), raising the potential that composite scores employing all three sources of 
information pointing to which genes are most sensitive to heterozygous mutation could add 
further value.
Discussion
We have developed a framework for evaluating excesses of de novo mutations identified 
through exome sequencing. Even though this framework can be leveraged to evaluate 
excesses of mutations study-wide and in gene sets, the key focus is to evaluate the 
significance for individual genes. Given the small number of observed de novo events per 
gene, simple case-control comparisons cannot achieve any meaningful level of significance. 
For example, observing three de novo LoF mutations in a small gene in 1,000 case trios is 
perhaps quite compelling; however, a simple 3 to 0 comparison with 1,000 control trios 
yields no compelling statistical evidence (one-tailed p=0.125). Incidence of such extremely 
rare events, however, can be evaluated if the expected rate of such events is known. 
Sequencing large numbers of control trios to gather empirical rate estimates on a per-gene 
basis that are accurate is infeasible and inefficient. The calibrated model and statistical 
approach described here can achieve a close approximation of this ideal. Our method, 
therefore, offers the ability to evaluate the rate of rare variation in individual genes in 
situations where burden tests would fail.
Other groups have developed similar statistical frameworks11,18 – notably, the Epi4k 
consortium18 used the same base model we begin with3 to interpret event rates. Our model, 
however, has two primary strengths. First, our model of de novo mutation incorporates 
additional factors beyond sequence context that affect mutation rate. Both the depth of 
coverage – how many sequence reads were present on average – for each base and the 
regional divergence around the gene between humans and macaques independently and 
significantly improve the predictive value of our model (Supplementary Note). Second, 
given the high correlation between the number of rare synonymous variants in ESP and the 
probability of a synonymous mutation determined by our full model, we have a metric to 
evaluate the extent to which genes in the human genome show evidence of selective 
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constraint. The list of 1,003 genes that we define as constrained contains an enrichment of 
genes known to cause severe human disease – an observation analogous to that recently 
made in using empirical comparison of common and rare rates of functional variation to 
evaluate intolerance8. In fact, site count deficits and site frequency shifts each contribute 
independent information to the definition of constraint and can in principle be combined in a 
composite test.
The results of our metric were compared to both the scores created by Petrovski and 
colleagues8 and loci identified as under negative selection by Bustamante et al 16. Overall, 
our metric and the residual variation intolerance scores defined by the Petrovski worked 
similarly well, reinforcing the benefits that could come from combining the two approaches. 
It is unsurprising that these methods outperform the evolutionary ones on the specific matter 
of genes intolerant to heterozygous mutation: longer term difference between polymorphism 
and fixed difference, more sensitive to weaker negative selection, require that mutations be 
tolerated well enough to become polymorphic in the first place whereas the absence of 
variation entirely will pick up the most strongly intolerant genes.
Ideally, we can conceptualize defining two metrics of genic constraint, one based on 
missense variants and the other based on LoF variants. With only 6,503 individuals in ESP, 
we are underpowered to determine significant deviations for most genes for the LoF 
variants. As sample size increases, our ability to calculate constraint improves. For example, 
if the sample size were to increase by an order of magnitude, we would be able to evaluate 
approximately 66% of genes using LoF variants. We therefore view the constrained gene list 
as a work in progress, to be updated when larger exome sequencing data sets become 
available.
Applying our statistical framework to de novo mutations from 1,078 ASD cases reveals that, 
while there is no global excess in de novo missense mutations, there are significantly more 
genes that contained multiple de novo missense mutations than expected. We also see 
significant overlap between the list of genes with a de novo LoF in ASD cases and the set of 
constrained genes that we defined. In addition, there is a significant overlap between the 
genes with a de novo LoF mutation and the targets of FMRP, as reported in Iossifov et al2. 
All of the significant signals in ASD – the global excess of de novo LoF mutations, the 
excess of genes with multiple functional de novo mutations, the overlap between the de novo 
LoF genes and both constrained genes and the targets of FMRP – are not found in the subset 
of ASD cases with IQ ≥ 100. The lack of signal in the IQ ≥ 100 indicates that genetic 
architecture among ASDs varies as a function of IQ. Overall, the probabilities of mutation 
defined by our full model and list of constrained genes can be used to critically evaluate the 
observed DNMs from sequencing studies and aid in the identification of variants and genes 
that play a significant role in disease.
Online Methods
De novo mutation information
Published de novo mutations were collected for both autism spectrum disorders (ASD)2–6 
and severe intellectual disability9,10. Updated de novo calls were provided from two of the 
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ASD studies3,5. Details about sample collection, sequencing, and variant processing can be 
found in the separate studies.
Additional sequencing
Exome sequencing of the additional families (n=129) was performed at the Broad Institute. 
Exons were captured using the Agilent 38 Mb SureSelect v2. After capture, another round of 
LM-PCR was performed to increase the quantity of DNA available for sequencing. All 
libraries were sequenced using an IlluminaHiSeq2000. Data were processed with Picard 
(http://picard.sourceforge.net/), which uses base quality-score recalibration and local 
realignment at known indels19 and BWA20 for mapping reads to hg19. SNPs were called 
using GATK for all trios jointly19,21. The variable sites that we have considered in analysis 
are restricted to those that pass GATK standard filters. From this set of variants, we 
identified putative de novo mutations and validate them as previously described3.
Mutational model
We wanted to create an accurate model of de novo mutation for each gene. In order to do so, 
we extended a previous sequence context-based model of de novo mutation to derive gene-
specific probabilities of mutation for each of the following mutation types: synonymous, 
missense, nonsense, essential splice site, and frameshift3. In brief, the local sequence context 
was used to determine the probability of each base in the coding region mutating to each 
other possible base and then determine the coding impact of each possible mutation. These 
probabilities of mutation were summed across genes to create a per-gene probability of 
mutation for the aforementioned mutation types (see Supplementary Note for more details). 
Here, we applied the method to exons and immediately flanking essential splice sites, but 
note that the framework is applicable to non-genic sequences. While fitting the expected 
rates of mutation to observed data, we added a term for local primate divergence across 1 
Mb (to capture additional unmeasured sources of regional mutational variability) and 
another for the average depth of sequence of each nucleotide (to capture inefficiency of 
variant discovery at lower sequencing depths); both terms significantly improved the fit of 
the model to observed data (details in Supplementary Note). We also investigated a regional 
replication timing term22, but found no evidence for it significantly improving the model 
(Supplementary Note).
To evaluate the predictive value of the model of de novo coding mutations, we extracted 
synonymous variants that were seen 10 times or fewer in the 6,503 individuals in the 
NHLBI’s Exome Sequencing Project (ESP) and compared the number of these rare variants 
in each gene to 1) the length of the gene and 2) the probability of a synonymous mutation 
for that gene determined by our model. While gene length alone showed a high correlation 
(0.880), our full model showed a significantly greater correlation (0.940, p < 10−16). Of 
note, the stochastic variability of counts from NHLBI ESP is such that if the model were 
perfect, the correlation to any instance of these data would be 0.975, indicating that little 
additional gene-to-gene variability remains to be explained. The relative rates of different 
types of coding mutations was quite similar to previous work based on primate 
substitutions23. With this calibrated model of relative mutability, we determined the absolute 
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expected mutation rate per gene by applying a genome-wide mutation rate of 1.2×10−8 per 
base pair per generation (Supplementary Note)24,25.
Removing potential false positive constrained genes
In order to identify genes that appeared to be significantly constrained, we used our 
probabilities of mutation to predict the expected amount of synonymous and 
nonsynonymous variation in the NHLBI’s ESP data. Those genes that had the expected 
amount of synonymous variation, but were significantly (p < 0.001) deficient for missense 
variation were labeled as constrained. To ensure that genes were not nominated as being 
constrained erroneously, we excluded from all analyses 134 genes where the observed 
synonymous and nonsynonymous rates were both significantly elevated or significantly 
depressed (both p < 0.001). Upon inspection, this list contained a number of genes that 
contained an internal duplication (e.g. FLG), a nearby pseudogene (e.g. AHNAK2), and a 
number of cases where recent duplications and/or annotation errors have led to the same 
sequence being assigned to two genes (e.g. SLX1A and SLX1B). These are all scenarios 
where standard exome processing pipelines systematically undercall variation – reads are 
unmapped due to uncertainty of which gene to assign them to – or overcall false variants 
owing to read misplacement. This further suggests that a byproduct of this analysis 
framework is the identification of a residual set of challenging genes for current exome 
sequencing pipelines.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
The expected and observed fraction of genes with a de novo loss-of-function mutation in 
ASD cases and unaffected controls for four gene sets of interest2–6,10,15. “Betancur” refers 
to a set of genes reported as disrupted in individuals with ASD or autistic features; of the 
112 on the list, we could evaluate 11112. “FMRP” refers to the genes whose mRNAs are 
bound and regulated by the Fragile X Mental Retardation Protein (FMRP), as identified by 
Darnell and colleagues13. The “constrained” category is a set of 1,003 genes that we defined 
as significantly lacking rare missense variation, indicating intolerance to mutation. The 
targets of FMRP that are also considered constrained by our metric make up the 
“Constrained FMRP” category. * indicates p < 0.01; ** indicates p < 10−4.
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Figure 2. 
The distribution of missense Z scores and Z scores of de novo loss-of-function mutations 
identified in unaffected individuals, autism spectrum disorder (ASD) cases, and intellectual 
disability cases. (a) The distribution of missense Z scores. The red line indicates a Z score of 
3.09, or the threshold for inclusion into the set of 1,003 constrained genes. (b) The missense 
Z scores for genes containing de novo LoF in unaffected individuals, ASD cases, and 
intellectual disability cases2–6,9,10,15. Black bars indicate the mean Z score of each group: 
0.94, 1.68, and 2.46 for unaffected individuals, ASD cases, and intellectual disability cases, 
respectively. While the missense Z scores of the de novo LoF mutations found in unaffected 
siblings matched the overall distribution (Wilcoxon p=0.8325, n.s. = not significant), de 
novo LoF mutations found in both ASD and intellectual disability cases were significantly 
shifted towards more extreme constraint values (p < 10−6 for both). All p-values for 
deviation from the overall distribution are listed on the right side of the figure in bold. In 
addition, the distribution of missense Z scores between each of the three de novo lists were 
all individually significant at p < 0.05.
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Table 1
Evaluation of the rates of de novo mutations in ASD cases and unaffected siblings. The observed and expected 
rate of mutations by type per exome for unaffected siblings2 and ASD cases, including some unpublished US 
and Finnish trios2–6 (a). (b) The number of genes with multiple de novo mutations in unaffected siblings and 
ASD cases across studies. The average number of expected genes with multiple de novo mutations was 
determined by simulation. LoF = Loss-of-function. DNMs = de novo mutations.
a) Genome-wide excesses of mutational events
Unaffected Siblings
Mutation Type Observed events per exome Expected events per exome p-value
Synonymous 0.21 0.27 0.0218 Two-tailed
Missense 0.61 0.62 0.8189 Two-tailed
Loss-of-Function 0.09 0.09 0.4508 One-tailed
n = 343 families
ASD Cases
Mutation Type Observed events per exome Expected events per exome p-value
Synonymous 0.25 0.27 0.1065 Two-tailed
Missense 0.64 0.62 0.5721 Two-tailed
Loss-of-Function 0.13 0.09 2.05E-07 One-tailed
n = 1,078 families
b) Genome-wide excesses of multiply hit genes
Unaffected Siblings
Mutation Type Observed genes with 2+ DNMs Average expected genes with 2+ DNMs p-value
Synonymous 0 0.5 1.0
Missense 5 2.5 0.1049
Loss-of-Function 0 0.04 1.0
LoF+missense 6 3 0.0779
n = 343 families
ASD Cases
Mutation Type Observed genes with 2+ DNMs Average expected genes with 2+ DNMs p-value
Synonymous 4 3.8 0.5186
Missense 33 21.4 0.0070
Loss-of-Function 6 0.5 < 0.001
LoF+missense 48 27.2 < 0.001
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ASD Cases
Mutation Type Observed genes with 2+ DNMs Average expected genes with 2+ DNMs p-value
n = 1,078 families
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Table 2
Individually significant genes identified from the analysis of de novo mutations in ASD cases. Genes with 
multiple loss-of-function (LoF) de novo mutations across 1,078 ASD cases. LoF mutations include nonsense, 
frameshift, and splice site-disrupting mutations. “# LoF Expected” refers to the expected number of de novo 
LoF mutations based on the probability of mutation for the gene as determined by our model. The genome-
wide significance threshold is 1×10−6
Gene Mutations # LoF Observed # LoF Expected p-value
DYRK1A nonsense, splice, frameshift 3 0.0072 6.15E-08
SCN2A nonsense, nonsense, frameshift 3 0.0178 9.20E-07
CHD8 nonsense, splice, frameshift 3 0.0221 1.76E-06
KATNAL2 splice, splice 2 0.0049 1.19E-05
POGZ frameshift, frameshift 2 0.0133 8.93E-05
ARID1B frameshift, frameshift 2 0.0178 1.57E-04
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Table 3
Evaluation of the rates of de novo mutations in cases with intellectual disability. (a) The observed and 
expected rate of mutations by type per exome for cases of intellectual disability (ID)9,10. (b) The number of 
genes with multiple de novo mutations in intellectual disability cases across studies. The average number of 
expected genes with multiple de novo mutations was determined by simulation. LoF = Loss-of-function. 
DNMs = de novo mutations.
a) Genome-wide excesses of mutational events
ID Cases
Mutation Type Observed events per exome Expected events per exome p-value
Synonymous 0.19 0.27 0.0267 Two-tailed
Missense 0.70 0.62 0.2380 Two-tailed
Loss-of-Function 0.24 0.09 6.49E-07 One-tailed
n = 151 families
b) Genome-wide excesses of multiply hit genes
ID Cases
Mutation Type Observed genes with 2+ DNMs Average expected genes with 2+ DNMs p-value
Synonymous 1 0.09 0.0879
Missense 3 0.5 0.0090
LoF 2 0.01 < 0.001
LoF+missense 6 0.6 < 0.001
n = 151 families
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